In-Depth Report COVID-19 Vaccines and U.S. Public Health Upheaval Targeted Fall Boosters, But Access Tightened: U.S. health authorities approved new monovalent COVID-19 vaccines (by Pfizer–BioNTech, Moderna, and Novavax) updated for the 2025–26 season reuters.com. Unlike prior booster rollouts, the FDA restricted under-65 eligibility to those with risk factors, aligning with guidance from HHS Secretary Robert…
Read more
Biotech & Pharma Industry Updates Regulatory & Drug Approvals Clinical Trials & Innovations Medical Research Highlights Health Policy & Government Public Health & Global Health Alerts Sources: This report draws on recent press releases and expert commentary from Reuters, AP, and industry outlets (with citations) to provide an accurate and timely summary of developments. Readers…
Read more
Regulatory Approvals & Clinical Milestones Pharma & Biotech Industry Moves Startups & Innovation Highlights Medical Research & Innovation Public Health & Policy Developments Sources: Ionis HAE drug approval pharmexec.com biopharmadive.com; BioPharmaDive on Dawnzera pricing and positioning biopharmadive.com biopharmadive.com; AbbVie Rinvoq AA trial via FiercePharma fiercepharma.com; Lancet Neurology SAPPHIRE trial results neurologylive.com neurologylive.com; Reuters – Kite/Gilead’s…
Read more
Major Corporate & Industry Announcements Clinical Trials & Drug Regulatory Updates Scientific & Medical Research Breakthroughs (Note: The above research highlights were reported in peer-reviewed journals and scientific news outlets around this time, underlining the broader scientific context during the news cycle.) Public Health & Policy Highlights Sources: Key information in this report is drawn…
Read more
Smartphones & Gadgets: Pixel Teasers and iPhone Rumors Cybersecurity: Telecom Ransomware Shock Space & Aerospace: Record Launches and New Missions Biotech & Health Tech: New Cures and Big Deals Tech Policy & Regulation: Trade Tensions and Antitrust Fines Autos & Mobility: Carmaker Alliances and EV Moves Sources: Reuters, Spaceflight Now, TechRadar, PhoneArena, MacRumors, TS2 Technology techradar.com…
Read more
For the period August 16–17, 2025, the biotech, pharma, medical, and health sectors saw a range of significant developments worldwide. Below is a comprehensive roundup of top stories categorized by theme, complete with expert insights and source links: Clinical Trial Results & Study Readouts Drug & Device Approvals Mergers, Acquisitions & Partnerships Public Health Alerts…
Read more
Wegovy (semaglutide) received FDA accelerated approval to treat metabolic dysfunction-associated steatohepatitis (MASH), becoming the first GLP-1 therapy cleared for MASH in a patient population estimated at about 5% of U.S. adults, based on part 1 of an ongoing trial showing liver health improvement. Tonix Pharmaceuticals’ Tonmya, or TNX-102 SL, was approved August 15 for fibromyalgia,…
Read more
IO Biotech’s Phase 3 melanoma vaccine Cylembia added to Merck’s Keytruda narrowly missed statistical significance, with median progression-free survival of 19.4 months versus 11 months for Keytruda alone. Fosun Pharma’s deal with Expedition Therapeutics grants rights outside Greater China to XH-S004, a first-in-class oral DPP-1 inhibitor for chronic respiratory diseases, in a pact potentially worth…
Read more
Novartis announced that two Phase III trials, NEPTUNUS-1 and NEPTUNUS-2, met their primary endpoints in Sjögren’s disease, marking the first global Phase III evidence of significant disease activity reduction with ianalumab and its dual B-cell depletion and BAFF signaling blockade. IO Biotech will disclose topline results from its Phase III melanoma trial of Cylembio (IO102-IO103)…
Read more
Drug Approvals & Regulatory Developments (In Europe, regulators also made news: the EMA’s committee recommended approving darolutamide (Bayer’s Nubeqa) with hormone therapy for metastatic prostate cancer based on positive Phase 3 data onclive.com.) Clinical Trials & Research Breakthroughs Public Health & Policy Industry & Business Updates Sources: Key information and quotes in this report were…
Read more
